Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Anxiolytic Drugs: Benzodiazepines and Buspirone01:29

Anxiolytic Drugs: Benzodiazepines and Buspirone

1.2K
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
1.2K
Sedatives and Hypnotics Drugs: Benzodiazepines01:19

Sedatives and Hypnotics Drugs: Benzodiazepines

375
Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
375
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

7.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.4K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.0K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.0K
Drug-Receptor Bonds01:25

Drug-Receptor Bonds

3.2K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
3.2K
The Equilibrium Binding Constant and Binding Strength02:18

The Equilibrium Binding Constant and Binding Strength

13.4K
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
13.4K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

P-Rex1 limits glucose clearance and suppresses hepatocyte glucose uptake and mitochondrial metabolism independently of its Rac-GEF activity.

Cell reports·2025
Same author

Structural and mechanistic insights into activators of alcohol dehydrogenase.

International journal of biological macromolecules·2025
Same author

Development of Novel Anticancer Pyrazolopyrimidinones Targeting Glioblastoma.

ChemMedChem·2025
Same author

Ultrasound-Mediated Drug Diffusion, Uptake, and Cytotoxicity in a Glioblastoma 3D Tumour Sphere Model.

Cells·2025
Same author

A review of the efficacy of prostate cancer therapies against castration-resistant prostate cancer.

Drug discovery today·2025
Same author

Effect of conventional and novel techniques on extraction yield, chemical characterisation and biological activities of proteins from bitter gourd (Momordica charantia).

Food chemistry·2024

Video Experimental Relacionado

Updated: Sep 9, 2025

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.7K

Perfiles de acoplamiento molecular y de unión específica de compuestos a base de benzosuberano

Michail A Saragatsis1,2,3, Gemma K Kinsella1,2,3, James F Curtin1,3

  • 1School of Food Science and Environmental Health, Technological University of Dublin, Grangegorman Lower, Dublin 7, D07 ADY7, Dublin, Ireland.

ChemMedChem
|September 3, 2025
PubMed
Resumen

Los compuestos de benzosuberano son prometedores como nuevos medicamentos para el cáncer. Los estudios computacionales revelan su potencial como agentes antivasculares y dirigidos al ADN, que ofrecen nuevas estrategias terapéuticas contra el cáncer.

Palabras clave:
Escafios de benzosuberanaBenzosuberona y sus derivadosel cáncerdiseño de fármacosModelado molecular

Más Videos Relacionados

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.5K
Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
08:49

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

521

Videos de Experimentos Relacionados

Last Updated: Sep 9, 2025

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.7K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.5K
Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
08:49

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

521

Área de la Ciencia:

  • Química medicinal
  • Diseño computacional de fármacos
  • En el campo de la oncología

Sus antecedentes:

  • El cáncer sigue siendo una de las principales causas de mortalidad, lo que requiere nuevos agentes terapéuticos debido a la resistencia a los medicamentos.
  • Los andamios de benzosuberana, que se encuentran en productos naturales, ofrecen flexibilidad estructural y diversas actividades biológicas, incluidos los efectos antitumorales.
  • Los avances en las terapias dirigidas ponen de relieve la necesidad de nuevos fármacos candidatos con mayor eficacia.

Objetivo del estudio:

  • Revisar los conocimientos computacionales que guían el diseño de compuestos a base de benzosuberano para la terapia del cáncer.
  • Para explorar los perfiles de interacción de los derivados del benzosuberano con diversos objetivos de cáncer.
  • Identificar agentes prometedores basados en benzosuberano para el futuro desarrollo de fármacos.

Principales métodos:

  • Se utilizaron estudios de acoplamiento molecular para analizar las interacciones de unión de los compuestos de benzosuberano.
  • Las ideas computacionales se consolidaron para comprender los principios de diseño de agentes antitumorales efectivos.
  • Se examinaron las relaciones estructura-actividad de los derivados de benzosuberano dirigidos a vías oncogénicas críticas.

Principales resultados:

  • Los compuestos de benzosuberano demostraron un potencial significativo como agentes antivasculares y intercaladores de ADN.
  • Se observaron afinidades de unión consistentes y citotoxicidad en las líneas celulares de cáncer de mama, pulmón y colon.
  • El acoplamiento molecular reveló perfiles de interacción detallados con objetivos clave de cáncer, regulando las vías oncogénicas.

Conclusiones:

  • Los compuestos a base de benzosuberano son candidatos prometedores para nuevas terapias contra el cáncer.
  • Los derivados de benzosuberano antivasculares y dirigidos al ADN muestran un potencial terapéutico particular.
  • Esta revisión sirve de guía para futuras investigaciones en el desarrollo de tratamientos contra el cáncer mediados por el benzosuberano.